Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Healthcare company Alliance Pharma said it expected underlying pre-tax profit to marginally top market expectations following 'strong' performance from its consumer healthcare brands.
See-through revenue for 2020 was down 5% on the prior year at £137.5 million.
Consumer healthcare revenues were up 1% to £93.0 million, while revenue from its prescription medicines were £44.5m, down 14% on the prior year, reflecting the negative impact of COVID-19 on the delivery of routine treatments for a large part of the year, the company said.
Looking ahead, the company said the acquisition of Biogix had brought Amberen into the group, a brand for the relief of menopause symptoms, and was expected to be earnings enhancing in FY 2021 and 'significantly' earnings enhancing from FY 2022.
At 9:14am: (LON:APH) Alliance Pharma PLC share price was 0p at 73.1p